News

Despite advancements over the years, cutaneous lupus erythematosus (CLE) continues to represent a high unmet medical need with no cure.

An ancillary study of the landmark VITAL trial provides clinicians with evidence related to the lack of reduction in fracture risk observed with vitamin D3 supplementation in older adults.

Patients with psoriatic arthritis (PsA) who have elevated interleukin-23 (IL-23) levels have been linked to higher rates of depression, anxiety, and disease activity.

The US FDA has approved belimumab for the treatment of active lupus nephritis in children aged 5 to 17 who are currently receiving standard therapy.

“The psychosocial burden of psoriatic arthritis (PsA) has been shown to have a negative effect on the quality of life of the patients. In PsA, psychological disorders can both cause and exacerbate disease development.”

“Qualitative research has identified that caregivers face many challenges that affect their well-being, including balancing their child’s demands with their own psychological needs when feeling depressed or stressed, and accompanying the child to the frequent health appointments.”

The analysis determined improvement based on a variety of clinical assessments, including the Leeds Enthesitis Index (LEI), Leeds Dactylitis Index (LDI), and modified Nail Psoriasis Severity Index (mNAPSI) scores, at baseline and week 24.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 23, 2022.

The feasibility study, “Fatigue – Reducing if Effects through individualized support Episodes in Inflammatory Arthritis” (FREE-IA), tested the practicality of training, intervention delivery, and outcome collection prior to a trial that would analyze clinical and cost-effectiveness.

25% of patients presented with extensive blood-brain barrier leakage, which was linked to both cognitive impairment and shorter disease duration.

“Understanding the impact of COVID-19 infection on children and young people with RMDs is important to inform national protection, education (such as school attendance), and vaccination guidance."

Previous assessments of the prevalence of lupus were conducted in short periods of time, therefore limiting the insight into long-term trends and potential explanations for the observed patterns.

C-reactive protein (CRP), an acute phase protein produced mainly by liver hepatocytes in response to interleukin-6 (IL-6), is a non-specific marker of inflammation.

Patients with rheumatoid arthritis (RA) have a higher risk of cancer, but does treatment of rheumatoid arthritis affect that risk? Test your knowledge with this quiz.

Treatment with apremilast was associated with extended time to biologic initiation when compared with treatment with methotrexate.

As treatment options expand in SLE with an increasing number of targeted therapeutics, we can be optimistic about the potential to improve disease outcomes.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 16, 2022.

"COVID-19 raises special concerns regarding its course and outcome among patients with IMIDs," investigators stated.

Further research examining a possible association between smoking, which was found more frequently in nADAb-positive patients, is warranted.

“These results show that emotional distress is associated with higher frequency of PFAPA attacks, thus may be considered as an environmental trigger for PFAPA attack," investigators stated.

Additional doses improved seroconversion and most vaccinated patients with lupus experienced a generally mild course of the disease.

Cancer is linked to many chronic conditions, but what is its relationship with rheumatoid arthritis? Test your knowledge with this quiz.

Novartis announces the EC expanded on the approval of secukinumab in EU to include pediatric patients with childhood arthritic conditions: juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.

Over a 40-year follow-up, approximately one-quarter of the study cohort with juvenile arthritis were reported to have active uveitis.

Higher energy and longer symptom duration at diagnosis were protective factors against medication failure.

New data suggests that a third COVID-19 booster might be warranted in children with juvenile idiopathic arthritis.

According to preliminary data, patients with JIA experience the same safety and immunogenicity as healthy individuals when vaccinated with the Pfizer COVID-19 vaccine.

Data suggests baricitinib not only significantly reduced the time to flares but also the frequency of flares in patients with JIA when compared with placebo.

A high percentage of pediatric patients with JIA do not achieve inactive disease during the first 2 years following diagnosis.

A new study revealed no significant relationship between patients with juvenile idiopathic arthritis and exposure to maternal infection, however, investigators said that suggestive evidence of differential sex-specific results indicate a need for further study.